Regel Therapeutics

About Regel Therapeutics

Regel Therapeutics is a biotechnology company focused on transforming the lives of people with severe genetic diseases through its Targeted EpiEditing platform, a precision genetic medicine approach that corrects gene expression in affected cells without altering the genome.

Products & Services

Targeted EpiEditing Platform:A pioneering technology using a deactivated CRISPR-Cas9 fused with an epigenetic modulator, delivered via AAVs with proprietary regulatory elements to correct abnormal gene expression exclusively in diseased cells.

RT101:A lead program targeting Dravet Syndrome, affecting approximately 17,000 patients across the US and Europe, currently in preclinical and IND-enabling stages advancing towards clinical trials.

Specialties

Precision Genetic Medicine Targeted EpiEditing CRISPR-Cas9 Technology Gene Therapy Vectors Treatment of Severe Genetic Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-dilutive Grant T: - FT: Non-dilutive Grant	A: 1000000 MR: - FA: 1 Million FAN: 1000000	D: 2023-09-29 FD: 2023-09-29	1 investors

Non-dilutive Grant Latest

2023-09-29

$1.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stephen J. Farr

CEO, Chairman of the Board

J

Jordane Dimidschstein

President & COO

K

Kathryn Allaway

VP of Research

M

Michael Jasulavic

Board Member

A

Andrew Schiermeier

Board Member

O

Orrin Devinsky

Chairman of the SAB

View 10 more team members with Pro

Unlock Full Team Directory

Recent News